Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | GYS1 | P13807 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | PPARD | Q03181 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518433 | 0.93 | APP (0.39) | KMT2AGYS1FFAR1PPARDTDP1 | |
| SCHEMBL518822 | 0.90 | MAOB (0.42) | KMT2AFFAR1PPARDPDE10APARP14 | |
| SCHEMBL519275 | 0.89 | KMT2A (0.43) | KMT2AFFAR1PPARDPDE10APARP14 | |
| SCHEMBL8369696 | 0.84 | PDE10A (0.42) | PDE10AALKBH1 | |
| SCHEMBL10259026 | 0.83 | MRGPRX4 (0.40) | KMT2AFFAR1PPARDALKBH1L3MBTL1 | |
| SCHEMBL7784391 | 0.80 | MAP2K1 (0.41) | KMT2APDE10AMEN1 | |
| SCHEMBL10258331 | 0.79 | MRGPRX4 (0.43) | KMT2AFFAR1PPARDALKBH1MRGPRX4 | |
| SCHEMBL10258841 | 0.78 | MRGPRX4 (0.44) | KMT2AFFAR1PPARDALKBH1MRGPRX4 | |
| SCHEMBL15004755 | 0.78 | APP (0.39) | KMT2APDE10AMEN1 | |
| SCHEMBL18793189 | 0.76 | CYP1A2 (0.37) | KMT2APDE10AL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | KMT2A 1726/4885GYS1 3864/4885FFAR1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.